Evidence map›Paper›PMID 33343924›Full record

ArticleVirus evolution2020

Genomic epidemiology of coxsackievirus A16 in mainland of China, 2000-18.

Zhenzhi Han, Yang Song, Jinbo Xiao, Lili Jiang, Wei Huang, Haiyan Wei, Jie Li, Hanri Zeng, Qiuli Yu, Jiameng Li and 13 more

Open access · goldAbstract read
In one paragraph

Article in Virus evolution, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 2 countries.

Zhenzhi HanWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.ORCID 0000-0003-1772-7946
Yang SongWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.ORCID https://orcid.org/0000-0002-7053-3836
Jinbo XiaoWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Lili JiangYunnan Center for Disease Control and Prevention, Kunming, Yunnan Province, People's Republic of China.
Wei HuangChongqing Center for Disease Control and Prevention, Chongqing City, People's Republic of China.
Haiyan WeiHenan Center for Disease Control and Prevention, Zhengzhou, Henan Province, People's Republic of China.
Jie LiBeijing Center for Disease Control and Prevention, Beijing City, People's Republic of China.
Hanri ZengGuangdong Center for Disease Control and Prevention, Guangzhou, Guangdong Province, People's Republic of China.
Qiuli YuHebei Center for Disease Control and Prevention, Shijiazhuang, Hebei Province, People's Republic of China.
Jiameng LiTianjin Center for Disease Control and Prevention, Tianjin City, People's Republic of China.
Deshan YuGansu Center for Disease Control and Prevention, Lanzhou, Gansu Province, People's Republic of China.
Yanjun ZhangZhejiang Center for Disease Control and Prevention, Hangzhou, Zhejiang Province, People's Republic of China.ORCID 0000-0002-2692-5437
Chonghai LiQinghai Center for Disease Control and Prevention, Xining, Qinghai Province, People's Republic of China.
Zhifei ZhanHunan Center for Disease Control and Prevention, Changsha, Hunan Province, People's Republic of China.
Yonglin ShiAnhui Center for Disease Control and Prevention, Hefei, Anhui Province, People's Republic of China.
Ying XiongJiangxi Center for Disease Control and Prevention, Nanchang, Jiangxi Province, People's Republic of China.
Xianjun WangShandong Center for Disease Control and Prevention, Jinan, Shandong Province, People's Republic of China.
Tianjiao JiWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Qian YangWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Shuangli ZhuWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Dongmei YanWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Wenbo XuWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.
Yong ZhangWHO WPRO Regional Polio Reference Laboratory and National Laboratory for Poliomyelitis, NHC Key Laboratory of Biosafety, NHC Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Changping District, Beijing, 102206, People's Republic of China.ORCID https://orcid.org/0000-0002-2692-5437
National Institute for Viral Disease Control and Prevention · CNChinese Academy of Sciences · CNTianjin Centers for Disease Control and Prevention · CNAnhui Provincial Center for Disease Control and Prevention · CNGansu Provincial Center for Disease Control and Prevention · CNHebei Provincial Center for Disease Control and Prevention · CNHenan Provincial Center for Disease Control and Prevention · CNHunan Provincial Center for Disease Control and Prevention · CNNanchang Center for Disease Control and Prevention · CNQinghai Institute for Endemic Diease Prevention and Control · CNShandong Center for Disease Control and Prevention · CNTaiwan Centers for Disease Control · TWWuhan Institute of Virology · CNYunnan Center for Disease Control And Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hand, foot, and mouth disease (HFMD), which is a frequently reported and concerning disease worldwide, is a severe burden on societies globally, especially in the countries of East and Southeast Asia. Coxsackievirus A16 (CV-A16) is one of the most important causes of HFMD and a severe threat to human health, especially in children under 5 years of age. To investigate the epidemiological characteristics, spread dynamics, recombinant forms (RFs), and other features of CV-A16, we leveraged the continuous surveillance data of CV-A16-related HFMD cases collected over an 18-year period. With the advent of the EV-A71 vaccine since 2016, which targeted the EV-A71-related HFMD cases, EV-A71-related HFMD cases decreased dramatically, whereas the CV-A16-related HFMD cases showed an upward trend from 2017 to October 2019. The CV-A16 strains observed in this study were genetically related and widely distributed in the mainland of China. Our results show that three clusters (B1a-B1c) existed in the mainland of China and that the cluster of B1b dominates the diffusion of CV-A16 in China. We found that eastern China played a decisive role in seeding the diffusion of CV-A16 in China, with a more complex and variant transmission trend. Although EV-A71 vaccine was launched in China in 2016, it did not affect the genetic diversity of CV-A16, and its genetic diversity did not decline, which confirmed the epidemiological surveillance trend of CV-A16. Two discontinuous clusters (2000-13 and 2014-18) were observed in the full-length genome and arranged along the time gradient, which revealed the reason why the relative genetic diversity of CV-A16 increased and experienced more complex fluctuation model after 2014. In addition, the switch from RFs B (RF-B) and RF-C co-circulation to RF-D contributes to the prevalence of B1b cluster in China after 2008. The correlation between genotype and RFs partially explained the current prevalence of B1b. This study provides unprecedented full-length genomic sequences of CV-A16 in China, with a wider geographic distribution and a long-term time scale. The study presents valuable information about CV-A16, aimed at developing effective control strategies, as well as a call for a more robust surveillance system, especially in the Asia-Pacific region.

Indexed as

coxsackievirus A16enterovirusepidemiologyphylodynamicsphylogeny

Identifiers

PMID33343924
PMCPMC7733612
OpenAlexW3112914135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.